Home › Xellia Enters 4 Year Collaboration To Develop New Antibiotics To Combat Multi-Drug Resistant Bacteria
 

Keywords :   


Xellia Enters 4 Year Collaboration To Develop New Antibiotics To Combat Multi-Drug Resistant Bacteria

2013-02-26 05:02:00| drugdiscoveryonline Home Page

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced recently that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria

Tags: year develop collaboration combat

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Martin Automatic celebrates successful return of drupa
28.06Pubco turns to HP for luxury packaging
28.06Rohit Aggarwal Joins Lenzing\'s Management Board and Named Designated CEO
28.06Fujitsu expert: I didn't think Horizon was a monster
28.06BCFs Coatings Ambassador Program Trains Its 50th Ambassador
28.06Cost of summer cookout reaches record high
28.06Heritage Environmental Services to Acquire EBV from General Dynamics
28.06Atlantic Tropical Weather Outlook
More »